Home Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology
Article
Licensed
Unlicensed Requires Authentication

Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology

  • Alexander D. Makatsariya EMAIL logo , Jamilya Khizroeva and Viktoriya O. Bitsadze
Published/Copyright: August 22, 2017

Abstract

Background:

Catastrophic antiphospholipid syndrome (CAPS) is an uncommon, often fatal, variant of the antiphospholipid syndrome (APS) that results in a widespread coagulopathy and high titres of antiphospholipid antibodies (aPL) and affects predominantly small vessels supplying organs with the development of multiorgan failure. It remains unclear why some patients develop the typical clinical picture of APS (thrombosis of large vessels), whereas others show the development of progressive microthrombosis, which the authors called “thrombotic storm” and multiple organ failure, that is, CAPS.

Materials and methods:

Since 2001–2016, we discovered 17 patients with CAPS development.

Conclusion:

CAPS is life-threatening condition, but optimal treatment for CAPS is not developed yet and the mortality rate is as high as 30%–40%.


Corresponding author: Alexander D. Makatsariya, MD, PhD Professor, Correspondent Member of the Russian Academy of Sciences, Head of the Chair of Obstetrics and Gynecology of Medical Prophylaxis Faculty of I.M. Sechenov First Moscow State Medical University, Vice-President of Russian Association of Obstetricians and Gynaecologists, Dmitrii Ulyanov Street 4-2-432, 119333 Moscow, Russia, Tel.: +7(903)728-0897
aAlexander D. Makatsariya, Jamilya Khizroeva and Viktoriya O. Bitsadze: These authors contributed equally to this article.
  1. Author’s statement

  2. Conflict of interest: Authors state no conflict of interest.

  3. Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.

  4. Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

References

[1] Antiphospholipid antibodies and thrombotic storm. J. Khizroeva. Proceedings of XIII All-Russian Scientific Forum “Mother and Child”. 2011, pp. 213–4.Search in Google Scholar

[2] Villa J, Marco A, Santamaria A, Mateo J, Simu M, Constans M, et al. Haemostasis and Thrombosis Unit, Haematology Service. Gynaecology and Obstetrics Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. 2006. The 2nd International symposium Women’s health issues in thrombosis and Haemostasis. Budapest, Hungary, Feb 4–6, 2005.Search in Google Scholar

[3] Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology. 2005;210:727–33.10.1016/j.imbio.2005.10.002Search in Google Scholar PubMed

[4] Walsh N. Clinical picture still emerging in CAPS registry. Ob Gyn News. 2006;41:25.Search in Google Scholar

[5] Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.10.1136/ard.2004.025759Search in Google Scholar PubMed PubMed Central

[6] The Catastrophic Antiphospholipid Syndrome (Asherson’s Syndrome). Monograph. Collected papers; 1992–2005. Printed by Creda Communications. 112 p.Search in Google Scholar

[7] Shoenfeld Y. The infectious etiology of APS: novel cross reactive epitopes on yeasts, bacteria and viruses. Immunobiology. 2005;209(Suppl S1). 2nd Tutzing Antiphospholipid Conference.Search in Google Scholar

[8] Vora SK, Asherson RA, Erkan D. Catastrophic antiphospholipid syndrome. J Intensive Care Med. 2006;21:144–59.10.1177/0885066606287041Search in Google Scholar PubMed

[9] Yasuda S, Atsumi T, Matsuura E, Kaihara K, Yamamoto D, Ichikawa K, et al. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum. 2005;52:212–8.10.1002/art.20741Search in Google Scholar PubMed

[10] Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphosphilipid syndrome. Curr Rheumatol Rep. 2010;12:70–6.10.1007/s11926-009-0073-6Search in Google Scholar PubMed

[11] Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.10.1016/j.autrev.2014.01.053Search in Google Scholar PubMed

[12] Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome – molecular mimicry? J Rheumatol. 2000;27:12–4.Search in Google Scholar

[13] Gharavi AE, Pierangeli SS, Harris EN. New developments in viral peptides and APL induction. J Autoimmun. 2000;15:227–30.10.1006/jaut.2000.0403Search in Google Scholar PubMed

[14] Karmochkine M, Mazoyer E, Marcelli A, Boffa MC, Piette JC. High prevalence of antiphospholipid antibodies in DIC. Thromb Haemost. 1996;75:971.10.1055/s-0038-1650403Search in Google Scholar

[15] Lai S, Walker DH, Elghetany MT. Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury – a case report with pathological and molecular correlative studies. Pathol Int. 2005;55:144–9.10.1111/j.1440-1827.2005.01798.xSearch in Google Scholar PubMed

[16] Makatsariya AD, Bitsadze VO, Dolgushina NV, Yudaeva LS, Khizroeva DH. Antiphospholipid syndrome – immune thrombophilia in obstetrics and gynecology. Moscow. 2007;456s. [M.Triada-X 2007-456s] [In Russian].Search in Google Scholar

[17] Bashiri A, Burstein E, Mazor M. Cerebral palsy and fetal inflammatory response syndrome: a review. J Perinat Med. 2006;34:5–12.10.1515/JPM.2006.001Search in Google Scholar PubMed

[18] Bernard GR, Vincent JL, Laterre PF, La Rosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C. Worldwide Evaluation in Severe Sepsis (PROWESSO study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.10.1056/NEJM200103083441001Search in Google Scholar

[19] Ruis-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.10.1016/S0140-6736(10)60709-XSearch in Google Scholar

[20] Kim S, Moskowitz N, Dicarlo E, Bass A, Erkan D, Lockshin M. Catastrophic antiphospholipid syndrome triggered by sepsis. Hosp Special Surg J. 2009;5:67–72.10.1007/s11420-008-9103-6Search in Google Scholar

[21] Lu CS, Horizon AA, Hwang KK, FitzGerald J, Lin WS, Wallace DJ, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum. 2005;52:4018–27.10.1002/art.21485Search in Google Scholar

[22] Carmona F, Lazaro I, Reverter JC, Tassies D, Font J, Cervera R, et al. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am J Obstet Gynecol. 2006;194:457–65.10.1016/j.ajog.2005.08.059Search in Google Scholar

[23] Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101:3495–500.10.1182/blood-2002-08-2349Search in Google Scholar

[24] Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter J-C, de la Red G . Thrombotic microangiopathic hemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.10.1136/ard.2003.007245Search in Google Scholar

[25] Le Thi Thuong D, Tieulie N, Costedoat N, Andreu MR, Wechsler B. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005;64:273–8.10.1136/ard.2003.019000Search in Google Scholar

[26] Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med. 1998;104:381–5.10.1016/S0002-9343(98)00061-8Search in Google Scholar

[27] Ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med. 2000;28:9–11.10.1097/00003246-200009001-00003Search in Google Scholar PubMed

[28] Asherson RA, Espinosa G, Cervera R. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005;64:943–6.10.1136/ard.2004.026377Search in Google Scholar PubMed PubMed Central

[29] Katzav A, Evert T, Pick CG, Blank M, Shoenfeld Y, Chapman J. Induction of antiphospholipid syndrome in Factor V Leiden mice. Immunobiology. 2005;209:10–11.Search in Google Scholar

[30] Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3:227–9.10.1111/j.1538-7836.2004.01090.xSearch in Google Scholar PubMed

[31] Lockshin MD, Pierangeli SS. Statins for the treatment of obstretic complications in antiphospholipid syndrome? J Reprod Immol. 2010;84:206.10.1016/j.jri.2009.11.007Search in Google Scholar PubMed

[32] Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843–9.Search in Google Scholar

[33] Sinthiya P, Khamashta MA. Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop. Curr Rheumatol Rep. 2013;15:318.10.1007/s11926-013-0318-2Search in Google Scholar PubMed

[34] Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus. 2013;22:865–7.10.1177/0961203313491023Search in Google Scholar PubMed

[35] Makatsariya AD, Bitsadze V, Khizroeva JK. Fetal thrombophilia and obstetrics complications. Pathophysiology of haemostasis and thrombosis. Proceeding and abstracts from the 19th International Congress on Thrombosis. Tel-Aviv, Israel, May 140–18, 2006:A10.Search in Google Scholar

Received: 2017-3-20
Accepted: 2017-7-4
Published Online: 2017-8-22
Published in Print: 2018-5-24

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Maternal medicine: an evolving discipline
  4. Corner of Academy
  5. Pregnancy after malignant disease – challenges and possibilities
  6. Review articles
  7. Animatio: a history of ideas on the beginning of personhood
  8. Expectant management of caesarean scar ectopic pregnancy: a systematic review
  9. Highlight articles
  10. Maternal outcomes in first and second trimester termination of pregnancy: which are the risk factors?
  11. A preliminary study of uterine scar tissue following cesarean section
  12. Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology
  13. Comparison of healthcare utilization and outcomes by gestational diabetes diagnostic criteria
  14. Adverse pregnancy outcomes and inherited thrombophilia
  15. Effect of female genital cutting performed by health care professionals on labor complications in Egyptian women: a prospective cohort study
  16. Letters to the Editor
  17. Effect of female genital cutting performed by health care professionals on labor complications in Egyptian women: methodological concerns
  18. Reply to: Effect of female genital cutting performed by health care professionals on labor complications in Egyptian women: methodological concerns
  19. Short communication
  20. Maternal plasma LPCAT 1 mRNA correlates with lamellar body count
  21. Original articles
  22. Experimental neonatal hypoxia ischemia causes long lasting changes of oxidative stress parameters in the hippocampus and the spleen
  23. Altered thymocyte and T cell development in neonatal mice with hyperoxia-induced lung injury
Downloaded on 23.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpm-2017-0092/html?lang=en
Scroll to top button